In the life sciences sector, millions of dollars in enterprise value rarely vanish overnight in a dramatic, catastrophic event. Instead, capital quietly bleeds out through subtle operational friction, misaligned clinical timelines, and miscalculated financial deal structures.
If your biotech company is struggling with unexplained capital burn or failing to reach expected valuation milestones, you need to find out the actual cause for it. While you might be cursing many external factors for it, such as the underlying cause from bad biology or anything else, the main point of concern that you might be overlooking has to be the leadership translation gap.
Before examining where your capital might be leaking, it is important that you undergo a reflection, observe where your leadership might be lacking, and seek to protect your runway and maximize pipeline value. To help you achieve this, Dr. David H. Crean’s Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences is a great resource that delivers a practical blueprint that helps executives, founders, and investors identify structural inefficiencies early, align clinical milestones with investor expectations, and avoid the silent value destroyers that drain modern biotechs.
If you are missing leadership capabilities that determine whether scientific breakthroughs become successful companies and meaningful therapies, the book explains that great science alone is not enough; leaders must also understand capital strategy, valuation, partnerships, and governance to make informed decisions at critical moments. By introducing the concept of Dual Fluency, David H. Crean provides you with the blueprint for scientific innovation and commercial success. As a result, you will gain insights into how to translate scientific data into investment opportunities, structure stronger deals, manage uncertainty, and build organizations capable of turning discoveries into patient impact.
That being said, as you read this book, it is also important to know how biotech companies frequently lose millions of dollars. It has to do with these four major operational seams:
- Funding to Calendar Dates Instead of Value-Accretive Milestones: Capital is often deployed based on rigid quarterly budgets rather than clear biological derisking inflection points. If a Phase I trial runs out of cash at 80% completion without reaching a definitive safety or biomarker readout, millions of dollars in research investment are effectively erased.
- Misaligned Deal Terms and Licensing Structures: Negotiating strategic partnerships or licensing deals without fully understanding both the clinical realities and financial covenants leads to costly mistakes. Structuring milestone payments around unrealistic regulatory timelines can lock core assets in perpetual litigation or force premature pipeline liquidation.
- Unnecessary Equity Surrender: Leaders who do not fully understand the complete spectrum of the capital stack—such as non-dilutive BARDA/NIH grants, royalty monetization, and structured venture debt—frequently default to traditional venture equity. This results in massive, unnecessary equity dilution for founders and early investors.
- Reluctance to Kill Lagging Programs Early: Academic research encourages exhaustive exploration, but commercial biotech requires ruthless capital prioritization. Boardrooms that lack deep scientific-financial integration often continue funding secondary programs long after the data suggests they should be terminated, burning millions that should have been preserved for the primary asset.
To stop the leak of precious capital, biotech leaders must learn to evaluate every scientific assay through a financial lens and every financial decision through a biological lens. Closing this gap is the single most effective way to protect your runway and carry life-saving therapies to market
